Orbimed Advisors LLC Gilead Sciences, Inc. Transaction History

Orbimed Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $7.6 Million - $8.67 Million	100,000 New	100,000 $7.71 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $5.72 Million - $6.53 Million	95,400 Added 49.64%	287,600 $18.6 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $92.5 Million - $107 Million	-1,278,900 Reduced 86.93%	192,200 $14.8 Million
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $71.7 Million - $91.9 Million	1,145,000 Added 351.12%	1,471,100 $110 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $4.72 Million - $5.21 Million	-75,500 Reduced 18.8%	326,100 $20.7 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $2.61 Million - $2.93 Million	-42,200 Reduced 9.51%	401,600 $27.1 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $4.79 Million - $6.26 Million	79,200 Added 21.72%	443,800 $27.8 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $11.4 Million - $13.9 Million	-157,000 Reduced 30.1%	364,600 $27.5 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $100 Million - $117 Million	-1,406,400 Reduced 72.95%	521,600 $37.4 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $139 Million - $165 Million	1,928,000	1,928,000 $156 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.